Merck & Co
EIKN icon

Merck & Co’s Eikon Therapeutics EIKN Stock Holding History

Merck & Co’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.4M Hold
1,666,666
– – 1.63% 5
2026
Q2 		$21.7M Hold
1,666,666
– – 4.13% 5
2026
Q1 		$17.6M Buy
+1,666,666
New +$22.3M 5.05% 5

Other funds holding EIKN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Regents of the University of California
Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
SCM
Soros Capital Management New York $182M AUM 108.83% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Merck & Co's EIKN Position: Q3 2026 in Review

Merck & Co held its Eikon Therapeutics (EIKN) position steady in Q3 2026 at 1,666,666 shares worth $13.4M. The position accounts for 1.63% of the portfolio, ranked #5.

Merck & Co first reported a position in EIKN in Q1 2026 and has held it in 3 quarters since. The position peaked at $21.7M in Q2 2026. 63 funds tracked by Wall St. Rank hold EIKN as of Q3 2026.

  • Merck & Co held 1,666,666 shares of Eikon Therapeutics worth $13.4M as of Q3 2026.
  • Merck & Co left its Eikon Therapeutics share count unchanged in Q3 2026.
  • Eikon Therapeutics made up 1.63% of Merck & Co's portfolio in Q3 2026, its #5 holding.
  • Merck & Co first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Merck & Co's Eikon Therapeutics position peaked at $21.7M in Q2 2026.
  • 63 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q3 2026.

Based on Merck & Co's 13F filing for Q3 2026, filed 13 Nov 2026.